01 September 2022>: Clinical Research
High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy
Iwona Homa-Mlak 1ACDEF* , Radosław Mlak 1ACDEF , Anna Brzozowska 2BDF , Marcin Mazurek 1CEF , Tomasz Powrózek 1CDF , Monika Prendecka-Wróbel 1CEF , Aneta Szudy-Szczyrek 2ADE , Piotr Dreher 3CEF , Katarzyna Kamińska 4F , Teresa Małecka-Massalska 1ACEF , Alicja Wójcik-Załuska 5CEGDOI: 10.12659/MSM.936857
Med Sci Monit 2022; 28:e936857
Table 5 Influence of demographic and clinical factors on nutritional status assessed by SGA scale in HNC patients.
Factor | SGA | ||||||
---|---|---|---|---|---|---|---|
A | B and C | pOR (95% CI) | A and B | C | pOR (95% CI) | ||
Gender | Male | 6 (13.6%) | 38 (86.4%) | 0.2352; 3.17 (0.47–21.24) | 28 (63.6%) | 16 (36.4%) | 0.8847; 1.14 (0.19–6.95) |
Female | 2 (33.3%) | 4 (66.7%) | 4 (66.7%) | 2 (33.3) | |||
Age (years) | ≥65 | 5 (23.8%) | 16 (76.2%) | 0.2109; 0.37 (0.08–1.76) | 12 (57.1%) | 9 (42.8%) | 0.3916; 1.67 (0.52–5.36) |
3 (10.3%) | 26 (89.7%) | 20 (68.9%) | 9 (31.1%) | ||||
Histopathological diagnosis | Carcinoma planoepitheliale | 6 (13.0%) | 40 (86.9%) | 0.0822; 6.67 (0.78–56.64) | 28 (60.9%) | 18 (39.1%) | 0.2456; 5.84 (0.30–115.00) |
Other | 2 (50%) | 2 (50%) | 4 (100%) | – | |||
Tumor location | Upper and middle | 2 (18.2%) | 9 (81.8%) | 0.8234; 0.82 (0.15–4.77) | 9 (81.8%) | 2 (18.2%) | 0.1778; 0.32 (0.06–1.68) |
Lower | 6 (15.4%) | 33 (84.6%) | 23 (59%) | 16 (41%) | |||
Lower and middle | 1 (20%) | 4 (80%) | 0.7977; 0.74 (0.07–7.61) | 5 (100%) | 0 | 0.1843; 0.14 (0.007–2.59) | |
Upper | 7 (15.6%) | 38 (84.4% | 27 (60%) | 18 (40%) | |||
T stage | T1–T2 | 2 (20%) | 8 (80%) | 0.7007; 0.71 (0.12–4.17) | 7 (70%) | 3 30%) | 0.6594; 0.71 (0.16–3.19) |
T3–T4 | 6 (15%) | 34 (85%) | 25 (62.5%) | 15 (37.5%) | |||
N stage | N0 | 4 (25%) | 12 (75%) | 0.2433; 0.40 (0.09–1.86) | 13 (81.3%) | 3 (18.7%) | 0.0063; 0.29 (0.07–1.22) |
N1–N3 | 4 (11.8%) | 30 (88.2%) | 19 (55.9%) | 15 (44.11%) | |||
M stage | M0 | 7 (14.9%) | 40 (8.5%) | 0.4163; 2.85 (0.22–35.91) | 30 (63.8%) | 17 (36.2%) | 0.9210; 1.13 (0.09–13.44) |
Mx and M1 | 1 (33.3%) | 2 (66.7%) | 2 (66.7%) | 1 (33.3%) | |||
Performance status (ECOG) | 1 | 8 (17.4%) | 38 (82.6%) | 0.6553; 0.50 (0.02–10.26) | 32 (69.6%) | 14 (30.4%) | 0.0487; 0.05 (0.002–0.98)* |
2 | – | 4 (100%) | – | 4 (100%) | |||
Irisin (ng/ml) | Low ( | 7 (28%) | 18 (72%) | 0.0449; 0.11 (0.01–0.95* | 18 (72%) | 7 (28%) | 0.2416; 0.49 (0.15–1.61) |
High (>Me) | 1 (4%) | 24 (96%) | 14 (56%) | 11 (44%) | |||
* Statistically significant results. ECOG – Eastern Cooperative Oncology Group; M – metastatic spread; N – lymph node involvement; T – tumor site and size. |